FDA Approves New Treatment Option for Patients with ALS

SILVER SPRING, Md., Sept. 29, 2022. The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig ' s disease. " This...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials